Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Position Reduced by Cutter & CO Brokerage Inc.

Cutter & CO Brokerage Inc. trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 721 shares of the medical research company’s stock after selling 36 shares during the period. Cutter & CO Brokerage Inc.’s holdings in Thermo Fisher Scientific were worth $383,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. WCM Investment Management LLC grew its position in Thermo Fisher Scientific by 0.3% in the fourth quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock worth $527,524,000 after acquiring an additional 2,928 shares in the last quarter. Phoenix Holdings Ltd. grew its position in Thermo Fisher Scientific by 21.4% in the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock worth $4,750,000 after acquiring an additional 1,654 shares in the last quarter. DMC Group LLC boosted its holdings in shares of Thermo Fisher Scientific by 16.5% during the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock worth $300,000 after buying an additional 84 shares during the period. S. R. Schill & Associates boosted its holdings in shares of Thermo Fisher Scientific by 106.3% during the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock worth $816,000 after buying an additional 792 shares during the period. Finally, Check Capital Management Inc. CA bought a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $219,000. 89.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

TMO has been the subject of several recent analyst reports. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. Evercore ISI upped their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. HSBC upped their price objective on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Royal Bank of Canada upped their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Finally, Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $475.00 to $555.00 in a research note on Wednesday, January 24th. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $604.69.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,547 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $550.62, for a total value of $3,054,289.14. Following the transaction, the chief executive officer now owns 43,608 shares of the company’s stock, valued at $24,011,436.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,277 shares of company stock worth $28,513,384. Company insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE:TMO traded up $1.68 during mid-day trading on Wednesday, reaching $576.27. 1,045,801 shares of the company were exchanged, compared to its average volume of 1,555,087. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company has a fifty day moving average of $572.03 and a 200 day moving average of $528.72. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The stock has a market cap of $219.97 billion, a PE ratio of 37.22, a PEG ratio of 2.31 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the prior year, the firm earned $5.40 EPS. The company’s revenue was down 4.9% on a year-over-year basis. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.